TICKERNERD
Menu
FHTXFHTXHealthcare · Biotechnology

FHTX Stock Forecast: Foghorn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.42
−1.56% on the day

The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $12 — +171.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$262.5M
Ticker Nerd rank
69 / 100
Median analyst target
$12
Analysts covering
10
Revenue$16.1M+112.7% y/y
Operating income−$8.8M
Net income−$7.2M
Free cash flow−$17.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.2%
1M
−32.9%
YTD
−18.1%
1Y
−16.3%
From 52W high
−37.5%
From 52W low
+25.2%
$3.53
$7.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FHTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
88
Revisions
85
Value
77
Size
64
Quality
56
Momentum
48
Accruals
41
Volatility
34
Issuance
14

Growth (88): Sales and profits are climbing, and climbing faster than before.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FHTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26FHTXHigh $14Median $12Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $9Median $12High $14

The green dot is the last close — the median target sits +171.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026WedbushReiteratesOutperform$10
10 Mar 2026HC Wainwright & Co.ReiteratesBuy$13
17 Feb 2026JefferiesMaintainsBuy—
18 Dec 2025BTIGInitiatesBuy—
4 Dec 2025StifelInitiatesBuy—
7 Nov 2025GuggenheimInitiatesBuy—
15 May 2025JMP SecuritiesReiteratesMarket Outperform—
30 Apr 2025HC Wainwright & Co.ReiteratesBuy—
30 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
23 Apr 2025JMP SecuritiesInitiatesMarket Outperform—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025B. Riley SecuritiesInitiatesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
16 Dec 2024JefferiesMaintainsBuy—
24 Sept 2024Morgan StanleyMaintainsEqual-Weight—
3 Sept 2024JefferiesInitiatesBuy—
19 Aug 2024Evercore ISI GroupInitiatesOutperform—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
9 Aug 2024WedbushReiteratesOutperform—
7 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FHTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FHTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Foghorn Therapeutics, Inc. returned −16.3% against +17.5% for the S&P 500, dividends included.

FHTX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26FHTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FHTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Foghorn Therapeutics, Inc. (FHTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.7×

Cheaper than 88% of US stocks

Price / sales
7.1×

Cheaper than 18% of US stocks

Price / book
−3.8×

Cheaper than 96% of US stocks

EV / EBITDA
−2.1×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
112.7%

Higher than 93% of US stocks

Earnings growth (YoY)
112.7%

Higher than 85% of US stocks

Gross margin
—
Operating margin
−54.8%

Higher than 16% of US stocks

Net margin
−175.8%

Higher than 3% of US stocks

Returns & dividend
Return on equity
68.5%

Higher than 94% of US stocks

Return on assets
−19.9%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Foghorn Therapeutics, Inc. (FHTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Foghorn Therapeutics, Inc. has a market value of $262.5M and an enterprise value of $138.0M.

  • Revenue in the twelve months to 30 June 2026: $36.7M. The latest quarter grew 112.7% year on year.

  • Net income over the same four quarters: −$64.6M, a −175.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$84.3M.

  • Shares outstanding: 58.7M.

  • Trailing P/E: −3.7×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Foghorn Therapeutics, Inc. employs 106 people — $347K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

FHTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FHTXFoghorn Therapeutics, Inc.$262.5M
69
PRQRProQR Therapeutics NV$256.8M
43
MGNXMacroGenics, Inc.$254.2M
65
TRDAEntrada Therapeutics, Inc.$264.0M
54
LCTXLineage Cell Therapeutics, Inc.$251.6M
55
CAMPCAMP4 Therapeutics Corp.$266.7M
65
PYXSPyxis Oncology, Inc.$267.7M
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FHTX news & analysis

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Zacks Investment Research · 26 Aug 2026positive

Zacks reports that the consensus analyst price target for Foghorn Therapeutics (FHTX) implies about 67% upside potential. The piece notes that while price targets are not a highly reliable metric, an upward trend in earnings estimate revisions could signal near-term upside for the stock.

Why it matters — FHTX watchers would care because the article highlights both a bullish analyst price target and a positive shift in earnings estimate revisions, both of which are factors often tracked when evaluating the stock's near-term outlook.

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Zacks Investment Research · 14 Aug 2026positive

Zacks Investment Research published a piece examining whether Foghorn Therapeutics (FHTX) qualifies as a strong momentum stock for investors to consider.

Why it matters — The article suggests FHTX may be gaining favorable attention from momentum-focused market participants, which could influence near-term trading dynamics.

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

Zacks Investment Research · 10 Aug 2026positive

Wall Street analysts' mean price target for Foghorn Therapeutics implies roughly 88.5% upside in the stock. While that price-target metric has historically not proven highly reliable, analysts' strong agreement in raising earnings estimates is cited as a signal of potential upside.

Why it matters — FHTX watchers would care because analyst consensus, particularly the collective upward revision of earnings estimates, is being highlighted as a possible indicator of improvement in the company's prospects.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Foghorn Therapeutics reported a second-quarter loss of $0.10 per share, narrower than both the Zacks Consensus Estimate of a $0.23 loss and the $0.28 loss recorded a year earlier. The company also beat revenue estimates for the quarter.

Why it matters — The result shows FHTX outperformed analysts' expectations for the quarter, with a smaller loss than forecast and than the prior year.

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

GlobeNewsWire · 6 Aug 2026positive

Foghorn Therapeutics released its second-quarter 2026 financial and corporate update, reporting approximately $168 million in cash, cash equivalents, and marketable securities with a cash runway into the first half of 2028. The company noted progress on its FHD-909 Phase 1 dose-escalation trial targeting non-small cell lung cancer, and said it is advancing selective EP300 degraders and a novel oral small molecule in immunology/inflammation, each with INDs targeted for 2027.

Why it matters — The update confirms pipeline advancement across oncology and immunology programs and reassures FHTX watchers about an extended cash runway into the first half of 2028, reducing near-term funding pressure.

FAQ

Frequently asked questions about FHTX stock

What is the FHTX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $9 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FHTX stock a buy right now?

Of the 10 analysts covering Foghorn Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FHTX?

As at 12 Sept 2026, Foghorn Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).

Will FHTX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +171.5% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 69 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FHTX stock forecast for 2030?

No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $14 over the next 12 months.

How has FHTX stock performed over the past year?

Foghorn Therapeutics, Inc. returned -16.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Foghorn Therapeutics, Inc. do?

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression.

What is the latest news on FHTX?

The most recent item we track (Zacks Investment Research, 26 Aug 2026): "Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet". Zacks reports that the consensus analyst price target for Foghorn Therapeutics (FHTX) implies about 67% upside potential. The piece notes that while price targets are not a highly reliable metric, an upward trend in earnings estimate revisions could signal near-term upside for the stock.

Company

About Foghorn Therapeutics, Inc.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.

CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com